Full text is available at the source.
Abstract
The review assesses evidence linking GLP-1 and GIP/GLP-1 receptor agonists with neuropsychiatric outcomes.
- Evidence was evaluated using the Bradford Hill criteria for assessing causality.
- Linkages between GLP-1 exposure and various neuropsychiatric outcomes were examined.
- Potential neuropsychiatric effects associated with GIP/GLP-1 receptor agonists were also considered.
- Findings may suggest important implications for understanding the impact of these treatments on mental health.
Simplified